Summary
The addition of vosaroxin to cytarabine improves overall survival and complete remission rates in patients with relapsed, refractory acute myeloid leukemia. This combination is not associated with increased early mortality. Patients at least age 60 years seemed to benefit more than younger patients.
- relapse
- refractory
- acute myeloid leukemia
- combination treatment
- overall survival
- vosaroxin
- cytarabine
- Study of Vosaroxin or Placebo in Combination With Cytarabine in Patients With First Relapsed or Refractory Acute Myeloid Leukemia (AML)
- VALOR
- NCT01191801
- © 2014 SAGE Publications
Tools
Vosaroxin in Combination With Cytarabine Provides a New Salvage Option for AML
Permalink:
Table of contents
Cited By...
- No citing articles found.